🇺🇸 Doxorubicin hydrochloride liposome in United States

256 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 39 reports (15.23%)
  2. Febrile Neutropenia — 37 reports (14.45%)
  3. Nausea — 36 reports (14.06%)
  4. Bone Marrow Failure — 26 reports (10.16%)
  5. Neutropenia — 26 reports (10.16%)
  6. Myelosuppression — 20 reports (7.81%)
  7. Disease Progression — 19 reports (7.42%)
  8. Vomiting — 19 reports (7.42%)
  9. Pancytopenia — 17 reports (6.64%)
  10. Thrombocytopenia — 17 reports (6.64%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Doxorubicin hydrochloride liposome approved in United States?

Doxorubicin hydrochloride liposome does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Doxorubicin hydrochloride liposome in United States?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.